Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

101.09 +0.40 (+0.40%)
Official Closing Price Updated: 7:00 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
News headline image
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Merck & Co., Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Deadline Alert: Merck & Co (MRK) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Deadline Approaching: Merck & Co (MRK) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edison, Elastic, Intellia, and Merck and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Law Offices of Frank R. Cruz Encourages Merck & Co (MRK) Investors to Inquire About Securities Fraud Class Action
From Law Offices of Frank R. Cruz
Via Business Wire
News headline image
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Merck & Co., Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Merck & Co (MRK) Investors To Inquire About Securities Fraud Class Action
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Merck to Participate in the TD Cowen 45th Annual Health Care Conference
From Merck & Co., Inc.
Via Business Wire
News headline image
Law Offices of Howard G. Smith Encourages Merck & Co (MRK) Investors To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Merck & Co (MRK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
MERCK & CO., INC. (NYSE: MRK) INVESTOR ALERT: Investors With Large Losses in Merck & Co., Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Merck & Co. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Filed Against MRK
From Robbins LLP
Via GlobeNewswire
News headline image
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
From Merck & Co., Inc.
Via Business Wire
News headline image
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
MRK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
MRK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Rosen Law Firm Urges Merck & Co., Inc. (NYSE: MRK) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Rosen Law Firm Encourages Merck & Co. Inc. Investors to Inquire About Securities Class Action Investigation – MRK
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.